A Double-blind, Randomised, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Increasing Multiple Oral Doses of Px-102 to Healthy Subjects
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs PX 102 (Primary)
- Indications Metabolic syndrome; Non-alcoholic fatty liver disease
- Focus Adverse reactions
- Sponsors Phenex Pharmaceuticals
- 17 Apr 2016 Results from human phase I study presented at The International Liver Congress™ 2016.
- 09 Dec 2013 New trial record